Kratom vs Kava

Walk into any American smoke shop, gas station, or “botanical” bar in 2026 and you will find kratom and kava sold a few feet apart, wrapped in the same language of natural, legal calm. Plenty of people use them interchangeably, or do not realise there are two entirely different plants involved. That is a mistake worth correcting, because underneath the shared marketing sit two completely different pharmacologies — one that touches the same receptors as morphine and heroin, and one that behaves more like a mild, plant-based anti-anxiety drink. This is education, not medical advice — but if you are going to reach for either, you should know which one you are actually holding.

We have covered each plant on its own in depth — our full deep dives on kratom and on kava go deeper on each — but the questions readers actually ask are comparative: Which is safer? Which is addictive? Which one calms anxiety? Which is legal? This article answers those head to head. (Educational overview only — not medical or use advice.)

Two plants, two worlds

Kratom (Mitragyna speciosa) is a tree in the coffee family, native to Southeast Asia. For generations, laborers in Thailand, Malaysia, and Indonesia chewed the fresh leaves or brewed them as a tea to fight fatigue, push through hard physical work, and manage pain and diarrhoea — sometimes as a substitute for opium (NCCIH). It is a plant of work and endurance.

Kava (Piper methysticum) is a member of the pepper family from the South Pacific, and its story is ceremonial rather than industrial. For thousands of years, Pacific Islanders have prepared a drink from the pounded root for ritual, hospitality, conflict resolution, and relaxation; the kava circle is a cornerstone of social and political life across Fiji, Vanuatu, Tonga, and Samoa (NCCIH; MSKCC). It is a plant of peace and community. That cultural split — the laborer’s stimulant versus the sacred relaxant — mirrors the pharmacology almost exactly.

The mechanism divide: opioid vs GABA

This is the crux of the entire comparison. Kratom is an opioid plant. Its principal alkaloids, mitragynine and 7-hydroxymitragynine (7-OH), bind the same mu-opioid receptors as codeine and morphine — and the FDA is blunt that they “may produce classic opioid-related effects such as sedation, nausea/vomiting, constipation, physical dependence/withdrawal, and respiratory depression that may lead to death” (FDA). Mitragynine also touches serotonin, dopamine, and adrenergic systems, which is why low doses feel stimulating.

Kava is a GABA plant. Its kavalactones work primarily by potentiating GABA-A receptors — the brain’s main inhibitory, calming system — but, notably, not through the same site as benzodiazepines. They add several other mechanisms: blocking voltage-gated sodium and calcium channels (reducing excitatory signalling) and mild, reversible inhibition of monoamine oxidase B. The result is muscle relaxation, anxiety relief, and a sociable calm — with, crucially, no opioid activity at all. In one sentence: kratom quiets you the way an opioid does; kava quiets you the way a gentle anxiolytic does. Everything else — the addiction profile, the overdose risk, the legal fights — flows from that one difference.

Kratom: the opioid leaf

Kratom’s defining feature is that it is dose-dependent. The DEA summarises it cleanly: consumption “produces both stimulant effects (in low doses) and sedative effects (in high doses)” (DEA). At a few grams, users report energy, alertness, talkativeness, and mild euphoria; at higher doses the opioid character takes over — sedation, pain relief, and the nausea and constipation familiar from any opioid. Roughly 1.7 million Americans aged 12 and over used kratom in 2021, most often to self-treat pain, anxiety, low mood, or — tellingly — opioid withdrawal and cravings (FDA).

That last use is the double edge. Because kratom is itself an opioid agonist, the same property that can blunt withdrawal from stronger opioids also means kratom can create its own dependence. The FDA documents users meeting criteria for a substance use disorder — escalating doses to get the same effect (tolerance) and experiencing withdrawal when they stop — and has even noted cases of neonatal withdrawal in newborns (FDA). This is not the mild, fuzzy “dependence” of caffeine; it is opioid-type dependence, and it is the single most important thing to understand before reaching for kratom.

Kava: the anxiolytic root

Kava’s profile is almost the mirror image: calming without the opioid dimension, and without the addiction. Its best-supported use is for anxiety. A Cochrane review of kava versus placebo found kava superior for anxiety symptoms, with adverse events that were “mild, transient and infrequent” — though the effect builds over weeks rather than in a single dose (Cochrane, Pittler & Ernst; NCCIH). Honesty requires a caveat, though: the evidence is genuinely mixed. A rigorous 16-week double-blind trial in generalized anxiety disorder was negative, and NCCIH now states plainly that “kava does not appear to be helpful for symptoms of generalized anxiety disorder” (NCCIH). The fair summary is that kava has real but contested anxiolytic evidence — more than most herbs, but not a settled cure. Kratom, by contrast, has no approved therapeutic use and almost no controlled human efficacy data.

Addiction: the sharpest contrast

If you remember one thing from this comparison, make it this. Kratom carries real, opioid-like dependence risk; regular users can develop tolerance and experience withdrawal — irritability, aches, insomnia, cravings — when they stop (NCCIH). Kava does not. Across the safety literature, kava is not associated with a dependence-and-withdrawal syndrome; its downsides (below) are about the liver and skin, not addiction. For someone whose goal is to relax or manage anxiety without risking a new dependency, that distinction alone often settles the choice.

Safety: two different failure modes

Both plants have real risks — but they fail in completely different ways.

Kratom’s risks center on its opioid nature and on product quality. The FDA flags “liver toxicity, seizures, and substance use disorder,” and unregulated products have been found contaminated with Salmonella and heavy metals. Deaths do occur, but the pattern matters: kratom is “usually used in combination with other drugs, and the contribution of kratom in the deaths is unclear” — fatal overdoses from kratom alone appear to be extremely rare (FDA; NCCIH). The genuinely dangerous frontier is not the leaf but the concentrate (next section).

Kava’s risks are the liver and the skin. Rare cases of serious — occasionally fatal — liver injury have been linked to various kava products; the first reports involved alcohol- or acetone-extracted supplements, and it has been suggested that poor-quality cultivars or the wrong plant parts (aerial stems rather than noble root) are to blame (NCCIH). Heavy, chronic use can also cause kava dermopathy — dry, scaly skin that reverses when use stops. And kava should never be combined with alcohol or other sedatives. The liver signal is why kava was banned in parts of Europe in the 2000s — bans that were later overturned as evidence pointed to product quality rather than properly prepared root.

The 7-OH crackdown (2025–2026)

The freshest and most important development in this whole space concerns kratom — and it is widely misunderstood. In 2025–2026, U.S. regulators moved not against the kratom leaf but against concentrated 7-hydroxymitragynine (“7-OH”) products. 7-OH is only a trace alkaloid in natural leaf (under 2% of the alkaloid content), but it is far more potent at the mu-opioid receptor than mitragynine — the FDA commissioner called it “an opioid that can be more potent than morphine” (FDA, July 2025). Manufacturers have been concentrating and synthesising 7-OH into gummies, shots, and tablets sold in gas stations and vape shops. In July 2025 the FDA recommended scheduling it; on July 1, 2026, the DEA began the temporary process to place 7-OH (and several synthetic derivatives) into Schedule I, with officials warning of a potential “fourth opioid epidemic” (FDA). The key nuance, which most coverage botches: these actions target concentrated/synthetic 7-OH extracts, not natural kratom leaf with only trace 7-OH. If you use kratom, this is the product category to avoid outright.

Legality in 2026

Their legal trajectories are moving in opposite directions. Kratom is federally legal and unscheduled — the DEA lists it as a “drug of concern” but it is not a controlled substance — yet the FDA does not permit it to be sold as a supplement or food, and it is banned outright in a handful of states (such as Alabama, Arkansas, Indiana, and Wisconsin) — even as a few states have recently reversed course — while many more have passed Kratom Consumer Protection Acts requiring age limits, lab testing, and honest labels (NCCIH; state statutes). With 7-OH scheduling underway, kratom’s legal picture is tightening. Kava, by contrast, is legal across the US, sold openly in kava bars and as a dietary supplement; internationally its story is one of loosening — the European bans were overturned and Australia liberalised kava imports in recent years. (State and national laws change quickly — verify where you live. This is not legal advice.)

Which one, and for whom

The two plants answer two different needs. People reach for kratom to fight fatigue and pain, for a stimulating lift at low doses, or to self-manage opioid withdrawal — but its opioid mechanism makes it a genuinely double-edged tool that can create its own dependence. People reach for kava for anxiety relief, social ease, and as an alcohol alternative — a calmer, lower-ceiling experience without the addiction risk. If your goal is relaxation or anxiety relief with the lowest dependence risk, kava is the more forgiving choice; if you are considering kratom, the harm-reduction essentials are to avoid concentrated 7-OH products, never mix it with other depressants (the dominant pattern in kratom-associated deaths is polydrug use), respect its real dependence potential, and buy only lab-tested product. For kava, use water-extracted noble-cultivar root, skip the alcohol/solvent extracts and aerial-part products tied to liver reports, and do not combine it with alcohol or sedatives.

The honest bottom line

Kratom and kava share a shelf and a reputation, but not a pharmacology. Kratom is an opioid in leaf form — useful to many, genuinely habit-forming, and now colliding with regulators over its potent 7-OH concentrates. Kava is a GABAergic anxiolytic in root form — a sacred Pacific drink with real (if contested) evidence for calm, a liver caution tied largely to product quality, and little addiction risk. Neither is a free lunch, and neither is a toy. But if you understand the one fault line that runs through this whole comparison — opioid versus GABA — every other difference, from withdrawal to overdose to the law, falls into place.

OOTW Journal is educational and does not provide medical advice. Kratom acts on opioid receptors and can cause dependence, withdrawal, and — especially as concentrated 7-OH or in combination with other drugs — serious harm; kava carries a rare risk of liver injury and should not be combined with alcohol or sedatives. Neither should be used with other central-nervous-system depressants, in pregnancy, or with liver disease without medical guidance. This article is not a guide to using any substance. If you are struggling with substance use, contact SAMHSA’s National Helpline (1-800-662-HELP) or, in crisis, the 988 Suicide and Crisis Lifeline (US). This article is education, not medical advice.